Teva Pharmaceutical Industries revenue and financials

TEVA · NYSE · USD

$39.13Change from previous close: −1.34%Absolute change: −$0.53

Close · October 6, 2026

In the fiscal year ended December 2025, Teva Pharmaceutical Industries reported revenue of $17.26B (+4.32% year over year). Net income was $1.41B, a net margin of 8.2%.

Annual revenue · 2025: $17.26B
  1. $21.9B2016
  2. $21.85B2017
  3. $18.27B2018
  4. $16.89B2019
  5. $16.66B2020
  6. $15.88B2021
  7. $14.93B2022
  8. $15.85B2023
  9. $16.54B2024
  10. $17.26B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+4.32%
2025 vs 2024
Net margin
8.2%
2024: -9.9%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Annual
Item202520242023FY to Sep 2023FY to Jun 2023FY to Mar 20232022202120202019
Total assets40,74839,32643,47942,09543,10043,46144,01147,66650,64057,470
Current assets13,94612,55212,485———12,05112,57313,00513,464
Cash and equivalents3,5563,3003,226———2,8012,1652,1771,975
Receivables3,7093,0593,408———3,696———
Inventory3,1793,0074,021———3,833———
Net property, plant and equipment4,4254,9486,147———6,158———
Goodwill16,00015,14717,177———17,63317,63320,62424,846
Other intangible assets3,7814,4185,387———6,270———
Current liabilities13,45612,79612,247———11,46911,02713,16413,674
Accounts payable2,5312,2032,602———1,887———
Long-term debt14,98616,00218,161———19,103———
Total debt17,09418,07920,153———21,561———
Total liabilities32,83433,60635,35334,70835,50834,95735,41336,42239,57942,407
Total equity (incl. minority)7,9145,7208,126———8,598———
Retained earnings-13,762-15,173-13,534———-12,975———
Minority interest4.0347620———794———